登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●二级市场交易风险。正平路桥建设股份有限公司（以下简称"公司"或"正平股份"）股票自2026年1月6 日至2026年1月9日期间连续4个交易日涨停，累计涨幅达20.74%；2026年1月12日至2026年1月14日连续 3个交易日跌停，跌幅达14.24%，触及《上海证券交易所交易规则》规定的股票交易异常波动情形。截 至目前，公司基本面未发生重大变化，公司股价剧烈交替走势积累了较高交易风险，投资者盲目参与可 能面临重大损失。请投资者关注公司存在的相关风险，理性决策，审慎投资。 ●公司预重整债权申报为部分债权申报，公司部分控股子公司未被纳入本次预重整债权申报范围，债权 申报准确性、完整性存在重大不确定性，公司可能难以通过本次债权申报消除非标意见所涉事项。公司 预重整债权申报涉及母公司及部分子公司债权申报及调查，公司部分控股子公司如贵州金九金、隆地电 力等均未被纳入本次预重整债权申报及债权调查范围。考虑到相关子公司业务规 ...

Core Viewpoint - Beijing Jinyu Group Co., Ltd. is expected to report a significant net loss for the fiscal year 2025, with preliminary estimates indicating a net profit attributable to shareholders ranging from -900 million to -1.2 billion yuan [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The estimated net profit attributable to shareholders is projected to be between -900 million and -1.2 billion yuan [4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between -3.45 billion and -3.75 billion yuan [4]. Group 2: Previous Year Performance - In the same period last year, the net profit attributable to shareholders was -55.516 million yuan, and the net profit after deducting non-recurring gains and losses was -285.939 million yuan [5]. Group 3: Reasons for Performance Change - The company's building materials and real estate businesses are currently in a down cycle, impacting overall performance [7]. - The cement business has improved, achieving profitability through strategic optimization and cost reduction efforts [7]. - The real estate sector is facing weakened demand and pressured sales prices, adversely affecting operating profits [7]. Group 4: Other Remarks - The cement business has seen significant cost reductions and improved operational management, leading to a turnaround in profitability [8]. - The company is focusing on technological innovation and the development of new materials, with successful applications in major projects [8]. - The real estate business is prioritizing profit stability and cash flow management, but some projects have not met sales price expectations, leading to a temporary decline in gross margins [9].

Core Viewpoint - International Medical (000516) has experienced a significant stock price increase, closing at 6.19 yuan on January 14, 2026, marking a 9.95% rise and achieving consecutive trading limits for two days [1]. Trading Information Summary - On January 14, 2026, the net outflow of main funds was 171 million yuan, while retail investors saw a net inflow of 143 million yuan [3][7]. - International Medical was listed on the "Dragon and Tiger List" due to a cumulative price deviation of over 20% in the last three trading days, marking its first appearance on the list in the past five trading days [4][7]. Company Announcement Summary - The controlling shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., pledged 75 million shares to Chang'an International Trust Co., Ltd. on January 13, 2026. This pledge accounts for 12.17% of its holdings and 3.35% of the company's total share capital. After this pledge, the total pledged shares by Century Xinyuan reached 82.07% of its holdings, with a combined pledge by Century Xinyuan and its concerted actions amounting to 24.61% of the company's total share capital. The company stated that the pledge risk is controllable and will not lead to a change in actual control [5]. - The company confirmed that from January 12 to January 14, 2026, its stock price experienced a cumulative deviation exceeding 20%, constituting abnormal trading fluctuations. The company has verified that there are no undisclosed significant matters, and its operational situation remains normal. The controlling shareholder and actual controller did not trade the company's stock during this period. The company is not involved in the research, production, or sales of brain-computer interface products, and related application revenue has a minimal impact on its performance [6][7].

易点天下1月14日公告，公司股票于2025年12月31日至2026年1月14日连续9个交易日收盘价涨幅偏离值 累计超过100%，属于股票交易严重异常波动的情况。股价波动较大，投资者较为关注，为维护投资者 利益，公司将就股票交易波动情况进行核查。经公司申请，公司股票自2026年1月15日开市起停牌，待 核查结束并披露相关公告后复牌，预计停牌时间不超过3个交易日。 ...

Core Viewpoint - The announcement from Hongbo Pharmaceutical indicates that the direct revenue from its DiOrion platform drug development services currently constitutes a small portion of the company's overall revenue, thus not significantly impacting its overall operational performance [1] Group 1 - Since January 8, the company's stock price has increased by more than its peers in the industry and has significantly outperformed related indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] - On January 14, Hongbo Pharmaceutical's stock closed up by 16.1%, with a closing price of 65.76 yuan per share [1] - The company warns that the continuous rise in stock price has accumulated considerable profit-taking adjustment risks, urging investors to fully understand secondary market trading risks and to make rational decisions [1]

Core Viewpoint - The company, Hongbo Pharmaceutical, has experienced significant stock price fluctuations since January 8, 2026, with a cumulative increase surpassing most peers in the industry and significantly exceeding the growth of relevant indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] Group 1 - The company's stock price has shown a substantial increase, leading to a higher profit adjustment risk due to accumulated gains [1] - A self-examination was conducted by the company, and a letter was sent to the controlling shareholder and actual controller for verification, confirming no undisclosed significant matters related to the company as of the announcement date [1] - The company's operations are currently normal, with no significant changes reported [1] Group 2 - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall operating income, indicating it does not significantly impact the overall business performance [1]

格隆汇1月14日｜湖南白银发布异动公告，公司股票连续三个交易日内日收盘价格涨幅偏离值累计达到 20%，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动的情况。近期国际银价出 现较大涨幅，公司白银产品未来市场价格能否继续上涨或维持高位存在不确定性，敬请投资者注意市场 风险。 ...

每经AI快讯，1月14日，光云科技发布股票交易异常波动暨严重异常波动公告称，公司股价显著偏离大 盘指数，短期波动幅度较大，已明显偏离市场走势，存在较高的炒作风险，如未来公司股票价格进一步 异常上涨，公司可能申请停牌核查，公司股票可能被上海证券交易所重点监控，异常交易相关投资者账 户可能被暂停交易。投资者参与交易可能面临较大风险，敬请广大投资者务必充分了解二级市场交易风 险，切实提高风险意识。 ...

Core Viewpoint - Tianpu Co., Ltd. has faced significant stock price volatility, leading to consecutive trading halts due to regulatory scrutiny and market rumors [4]. Group 1: Regulatory Actions - On January 9, Tianpu Co., Ltd. received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) due to abnormal stock trading and alleged major omissions in announcements [4]. - The CSRC decided to initiate an investigation into the company based on relevant laws and regulations [4]. Group 2: Stock Trading and Market Response - Following the investigation notice, Tianpu Co., Ltd. resumed trading on January 12, but the stock faced a limit down on the first day of trading [2]. - The company issued a clarification announcement on January 12, addressing false rumors circulating among investors, stating that the actual controller's comments at a public event were misinterpreted [4].

Core Viewpoint - The stock of Zhangpeng Technology Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price deviation exceeding 20% over three consecutive trading days in January 2026, prompting the company to issue a notice regarding the situation [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly on January 9, 12, and 13, 2026, leading to a cumulative price deviation of over 20%, which is classified as abnormal trading behavior according to Shanghai Stock Exchange regulations [2][4]. - The company confirmed that there are no undisclosed significant matters affecting the stock price fluctuations, and all previously disclosed information is accurate and complete [5][7]. Group 2: Financial Performance - For the first three quarters of 2025, the company's revenue was approximately 226 million yuan, with a net loss attributable to shareholders of about 54 million yuan, indicating a loss situation [6]. - The military simulation business reported a negative net profit and declining gross profit margin compared to the previous year, failing to meet expectations [5][6]. - The company anticipates a risk of goodwill impairment of approximately 276 million yuan due to the acquisition of control over Lingwei Military Finance, which may impact the financial results for 2025 [5][6]. Group 3: Company Operations - The company stated that its operational status is normal, with no significant changes in daily operations or external environment affecting the stock price [5]. - There are no major undisclosed events, such as asset restructuring or significant transactions, that could influence the stock's trading behavior [7][10].